Qiagen Submits Second PMA for Therascreen KRAS Companion Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen today said that it has submitted a second Premarket Approval application to the US Food and Drug Administration for its therascreen KRAS RGQ PCR Kit for use a companion diagnostic with metastatic colorectal cancer drug Erbitux (cetuximab).

Erbitux is sold in the US by Bristol-Myers Squibb and Eli Lilly. Outside of the US and Canada, it is sold by Germany's Merck KGaA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.